Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dabigatran

- PMLiVE

Boehringer taps Korea’s Bridge for Ofev follow-up

Latest in a string of in-licensing deals

- PMLiVE

Kisqali combination follows Verzenio onto Cancer Drugs Fund

Drug must prove its value via managed access route

- PMLiVE

AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

New fast-track appraisal a boon for companies

- PMLiVE

UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D

Pilot much more to industry liking, but devil will be in detail

- PMLiVE

Boehringer tests speech as early warning for CNS diseases

Company extends foray into digital health innovation

- PMLiVE

NICE backs CDF funding for Sanofi/Regeneron’s skin cancer drug Libtayo

Acknowledges unmet need

- PMLiVE

Boehringer bolsters NASH pipeline with $870m Yuhan deal

Strengthens existing relationship

- PMLiVE

FDA fast-tracks Jardiance for heart failure review

Would challenge Novartis' Entresto

- PMLiVE

Boehringer eyes rare disease use for respiratory blockbuster

Would help support respiratory franchise

- PMLiVE

With Spiriva under pressure, Boehringer moves to bolster pipeline

Forges alliance with PureTech Health

- PMLiVE

Akcea steals march on Alnylam with NICE approval

Advantage to Tegsedi over Onpattro

- PMLiVE

NICE says no to Novartis’ Kisqali combo in breast cancer

Double blow after Lilly rival recommended

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links